Brigatinib is an investigational small-molecule orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity.
Brigatinib is white to off-white in colour and insoluble in water.
MW: 584.102 g/mol
CAS No. 1197953-54-0
Notice: If the compound involved in patent protection, do not use for commercial purposes, and only for the purpose of analysis and research experiments. If it’s sold to countries which constitute patent infringement, All the risks corresponding are unrelated to our company.